Product Overview
Retatrutide 50mg Canada - LY3437943 Research Peptide
Retatrutide 50mg from Precision Synthetics Canada is a lyophilized research peptide supplied in a sealed 3 mL glass vial for laboratory research and analytical use.
Retatrutide, also known as LY3437943 or LY-3437943, is studied as a triple receptor agonist across the glucagon, GIP, and GLP-1 receptor pathways. Its multi-incretin profile has made it a high-interest compound in research involving body-weight models, metabolic signaling, receptor activity, glycemic endpoints, energy expenditure, and body-composition research.
Precision Synthetics Canada takes a safety-first approach to research peptide supply. Each released batch is supported by Janoshik source-lab documentation, independent Testide Canada Laboratory verification, and LAL endotoxin screening through Testide for supported batches. This gives Canadian research buyers more than a purity percentage by adding visibility into identity, purity, batch traceability, and endotoxin screening.
Key Highlights
50 mg lyophilized Retatrutide per vial
Also known as Retatrutide, LY3437943, and LY-3437943
Triple GCGR / GIPR / GLP-1R receptor agonist research compound
Sealed 3 mL glass vial with batch-labeled traceability
Janoshik Laboratory source-lab documentation
Independent Testide Canada Laboratory verification arranged by Precision Synthetics Canada
LAL endotoxin screening through Testide for added batch-quality review
COA access for supported batches
Ships from Vancouver, Canada
LAL Endotoxin Screening + Dual Third-Party Review
Purity matters, but it is only one part of responsible batch review. Precision Synthetics Canada puts extra emphasis on LAL endotoxin screening because many research peptide listings stop at HPLC purity alone and do not show this additional endotoxin-screening layer.
For supported batches, Retatrutide research material is reviewed through a layered documentation model: Janoshik source-lab documentation, independent Testide Canada Laboratory verification, and LAL endotoxin screening through Testide. This gives research buyers more than a single supplier document by adding visibility into identity, purity, traceability, chromatogram data, report date, sample reference, batch linkage, endotoxin screening, and verifiable report information when available.
LAL endotoxin screening: an added quality-control datapoint used to assess bacterial endotoxin presence in the submitted sample.
Janoshik Laboratory: source-lab testing documentation connected to the originating production batch, including identity and purity information.
Testide Canada Laboratory: independent verification arranged by Precision Synthetics Canada before supported batches are released, including LAL endotoxin screening where applicable.
COA Transparency
COA access is provided for supported batches through batch-linked documentation, QR code access, or a product documentation page. For more information, visit COA Transparency.
Some Janoshik source-lab COAs may include limited redactions to protect upstream laboratory confidentiality and prevent unauthorized or unsolicited contact with source-lab partners. These redactions may apply to identifying or commercially sensitive details and are not intended to obscure analytical results.
Research Profile
Retatrutide is studied as a multi-incretin research peptide because of its activity across three receptor pathways:
Pathway Research Relevance
GCGR Glucagon receptor pathway research
GIPR Glucose-dependent insulinotropic polypeptide receptor research
GLP-1R Glucagon-like peptide-1 receptor research
Common research areas include:
Body-weight and obesity research models
Triple glucagon/GIP/GLP-1 receptor agonism
Multi-incretin pathway signaling
cAMP signaling and receptor potency studies
Receptor selectivity and comparative activity
Glycemic endpoint research
Insulin-response and metabolic biomarker models
Energy expenditure and food-intake research models
Body weight, fat mass, and lean mass partitioning models
Comparative pharmacology involving semaglutide, tirzepatide, and other incretin analogs
Analytical identity, purity, endotoxin screening, and batch-to-batch review
Retatrutide is sometimes searched informally as "triple GLP" or "GLP-3", but the accurate research description is triple glucagon/GIP/GLP-1 receptor agonist.
Review the Retatrutide research papers page for published study references, mechanism notes, and endpoint data.
Product Details
Specification Details
Product name Retatrutide 50mg
Brand Precision Synthetics Canada
Synonyms LY3437943, LY-3437943
Product type Research peptide
Research class Triple glucagon/GIP/GLP-1 receptor agonist
Net content 50 mg per vial
Format Lyophilized material
Appearance White to off-white lyophilized material
Container Sealed 3 mL glass vial
Approximate vial weight 0.005 kg, about 5 g
Lot/batch ID Recorded on vial label
Testing model Janoshik source-lab documentation + Testide Canada Laboratory verification
Endotoxin screening LAL endotoxin screening through Testide Canada Laboratory for supported batches
COA access Batch-linked documentation for supported batches
Shipping origin Vancouver, Canada
Shipping availability Canada only
Intended use Research use only
Compound Identity
Field Information
Compound Retatrutide
Synonyms LY3437943, LY-3437943
CAS 2381089-83-2
Molecular formula C221H342N46O68
Molecular weight Approximately 4731.35 g/mol
Research category Long-acting multi-incretin analog
Receptor pathways GCGR, GIPR, GLP-1R
Canadian Shipping
Orders ship from Vancouver, Canada. Shipping is currently available within Canada only.
Intended Use
Retatrutide 50mg is supplied for laboratory research, analytical reference work, assay development, and non-clinical research applications.
FAQ
What is Retatrutide?
Retatrutide, also known as LY3437943 or LY-3437943, is a synthetic research peptide studied for activity across the glucagon, GIP, and GLP-1 receptor pathways.
Is this Retatrutide third-party tested?
Yes. Each released batch is supported by Janoshik source-lab documentation and independent Testide Canada Laboratory verification arranged by Precision Synthetics Canada.
Does this product include LAL endotoxin screening?
Released batches include LAL endotoxin screening through Testide Canada Laboratory for supported batches. This adds another quality-control datapoint for research buyers.
Does this product include a COA?
Applicable released batches are supported by batch-linked COA documentation. COA access may be provided through a QR code, report link, or batch documentation page.
Where does this product ship from?
Retatrutide 50mg ships from Vancouver, Canada, with shipping currently available within Canada only.
Is Retatrutide the same as GLP-3?
No. "GLP-3" is an informal search term sometimes used online. The accurate research description is triple glucagon/GIP/GLP-1 receptor agonist.
